Logo image of BRTX

BIORESTORATIVE THERAPIES INC (BRTX) Stock Fundamental Analysis

NASDAQ:BRTX - Nasdaq - US0906556065 - Common Stock - Currency: USD

1.75  +0.02 (+1.17%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BRTX. BRTX was compared to 568 industry peers in the Biotechnology industry. The financial health of BRTX is average, but there are quite some concerns on its profitability. BRTX is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BRTX had negative earnings in the past year.
BRTX had a negative operating cash flow in the past year.
BRTX had negative earnings in each of the past 5 years.
BRTX had a negative operating cash flow in each of the past 5 years.
BRTX Yearly Net Income VS EBIT VS OCF VS FCFBRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

BRTX has a Return On Assets of -73.12%. This is in the lower half of the industry: BRTX underperforms 66.90% of its industry peers.
BRTX has a Return On Equity (-105.25%) which is in line with its industry peers.
Industry RankSector Rank
ROA -73.12%
ROE -105.25%
ROIC N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
BRTX Yearly ROA, ROE, ROICBRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 92.99%, BRTX belongs to the best of the industry, outperforming 92.78% of the companies in the same industry.
BRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BRTX Yearly Profit, Operating, Gross MarginsBRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K -80K

More info and screens

5

2. Health

2.1 Basic Checks

BRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BRTX has been increased compared to 1 year ago.
Compared to 5 years ago, BRTX has more shares outstanding
There is no outstanding debt for BRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BRTX Yearly Shares OutstandingBRTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
BRTX Yearly Total Debt VS Total AssetsBRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

2.2 Solvency

BRTX has an Altman-Z score of -18.16. This is a bad value and indicates that BRTX is not financially healthy and even has some risk of bankruptcy.
BRTX has a Altman-Z score of -18.16. This is amonst the worse of the industry: BRTX underperforms 84.68% of its industry peers.
BRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -18.16
ROIC/WACCN/A
WACC10.33%
BRTX Yearly LT Debt VS Equity VS FCFBRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

BRTX has a Current Ratio of 2.97. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
BRTX has a worse Current ratio (2.97) than 65.14% of its industry peers.
BRTX has a Quick Ratio of 2.97. This indicates that BRTX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.97, BRTX is doing worse than 63.03% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.97
Quick Ratio 2.97
BRTX Yearly Current Assets VS Current LiabilitesBRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 66.93% over the past year.
The Revenue has grown by 187.87% in the past year. This is a very strong growth!
The Revenue has been growing by 25.27% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)66.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.91%
Revenue 1Y (TTM)187.87%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%127.89%

3.2 Future

Based on estimates for the next years, BRTX will show a very strong growth in Earnings Per Share. The EPS will grow by 51.61% on average per year.
The Revenue is expected to grow by 207.33% on average over the next years. This is a very strong growth
EPS Next Y-10.41%
EPS Next 2Y12.81%
EPS Next 3Y43.72%
EPS Next 5Y51.61%
Revenue Next Year158.1%
Revenue Next 2Y89.77%
Revenue Next 3Y288.05%
Revenue Next 5Y207.33%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BRTX Yearly Revenue VS EstimatesBRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
BRTX Yearly EPS VS EstimatesBRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BRTX Price Earnings VS Forward Price EarningsBRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BRTX Per share dataBRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

BRTX's earnings are expected to grow with 43.72% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.81%
EPS Next 3Y43.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIORESTORATIVE THERAPIES INC

NASDAQ:BRTX (4/17/2025, 8:04:48 PM)

1.75

+0.02 (+1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-28 2025-03-28/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners13.91%
Inst Owner Change0%
Ins Owners27.05%
Ins Owner Change0%
Market Cap12.11M
Analysts82.5
Price Target13.26 (657.71%)
Short Float %14.32%
Short Ratio1.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.07%
Min EPS beat(2)28.7%
Max EPS beat(2)69.45%
EPS beat(4)4
Avg EPS beat(4)37.1%
Min EPS beat(4)12.47%
Max EPS beat(4)69.45%
EPS beat(8)7
Avg EPS beat(8)23.9%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-62.76%
Min Revenue beat(2)-91.06%
Max Revenue beat(2)-34.45%
Revenue beat(4)2
Avg Revenue beat(4)121.24%
Min Revenue beat(4)-91.06%
Max Revenue beat(4)481.7%
Revenue beat(8)6
Avg Revenue beat(8)104.57%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)-25%
EPS NY rev (1m)13.1%
EPS NY rev (3m)13.1%
Revenue NQ rev (1m)-39.49%
Revenue NQ rev (3m)-42.34%
Revenue NY rev (1m)-17.34%
Revenue NY rev (3m)-17.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 30.2
P/FCF N/A
P/OCF N/A
P/B 1.42
P/tB 1.53
EV/EBITDA N/A
EPS(TTM)-1.16
EYN/A
EPS(NY)-1.29
Fwd EYN/A
FCF(TTM)-1.2
FCFYN/A
OCF(TTM)-1.19
OCFYN/A
SpS0.06
BVpS1.23
TBVpS1.14
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -73.12%
ROE -105.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.99%
FCFM N/A
ROA(3y)-89.42%
ROA(5y)-144.93%
ROE(3y)-108.73%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 56.16%
Cap/Sales 26.48%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.97
Quick Ratio 2.97
Altman-Z -18.16
F-Score5
WACC10.33%
ROIC/WACCN/A
Cap/Depr(3y)175.34%
Cap/Depr(5y)N/A
Cap/Sales(3y)170.15%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%64.91%
EPS Next Y-10.41%
EPS Next 2Y12.81%
EPS Next 3Y43.72%
EPS Next 5Y51.61%
Revenue 1Y (TTM)187.87%
Revenue growth 3Y100.17%
Revenue growth 5Y25.27%
Sales Q2Q%127.89%
Revenue Next Year158.1%
Revenue Next 2Y89.77%
Revenue Next 3Y288.05%
Revenue Next 5Y207.33%
EBIT growth 1Y24.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-26.29%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28%
OCF growth 3YN/A
OCF growth 5YN/A